Alzheimer’s disease is a neurodegenerative disease
caused by excessive amyloid β protein-induced neurotoxicity.
However, drugs targeting
amyloid β protein production face many problems, such as the
low utilization rate of drugs by cells and the difficulty of drugs
in penetrating the blood–brain barrier. A tetrahedral framework
nucleic acid is a new type of nanonucleic acid structure that functions
as a therapy and drug carrier. Here, we synthesized a BACE1 aptamer-modified
tetrahedral framework nucleic acid and tested its therapeutic effect
on Alzheimer’s disease in vitro and in vivo. Our results demonstrated that the tetrahedral framework
nucleic acid could be used as a carrier to deliver the BACE1 aptamer
to the brain to reduce the production of amyloid β proteins.
It also played an antiapoptotic role by reducing the production of
reactive oxygen species. Thus, this nanomaterial is a potential drug
for Alzheimer’s disease